No Data
No Data
No Data
No Data
No Data
Shanghai Henlius Biotech Doses 1st Patient in Fibrosis Drug Clinical Study in China
Shanghai Henlius Biotech (HKG:2696) has dosed the first subject in a phase I clinical study of HLX6018 in healthy subjects in mainland China, a Tuesday filing on the Hong Kong bourse stated. HLX6018 i
MT NewswiresApr 24 05:28 ET
Fu Hong Han Lin (02696): The phase 1 clinical study of HLX6018 in healthy subjects completed the first patient administration in China
Fu Hong Han Lin (02696) announced that recently, HLX6018 (recombinant anti-GARP/TGF-beta1...
Zhitong FinanceApr 23 04:51 ET
Henlius Biotech Gets Clearance for China Clinical Trial of Carcinoma Drug
Shanghai Henlius Biotech's (HKG:2696) clinical trial application for HLX53 has been approved by the National Medical Products Administration of China, a Wednesday filing on the Hong Kong bourse said.
MT NewswiresApr 17 05:38 ET
Fu Hong Han Lin (02696.HK): A clinical trial application for HLX53 combined with Hans-type and Hanbeitai for first-line treatment of locally advanced or metastatic hepatocellular carcinoma was approved by the State Drug Administration
Gelonghui, April 17, 丨 Fu Hong Han Lin (02696.HK) issued an announcement. Recently, the clinical trial application for HLX53 (anti-Tigit FC fusion protein) (“HLX53”) combined with Hans form (sululimab injection) (“Hans form”) and Hanbetai (bevacizumab injection) (“Hanbetai”) for first-line treatment of locally advanced or metastatic hepatocellular carcinoma (HCC) was approved by the National Drug Administration (“NMPA”). The company plans to be in China after the conditions are met (excluding Hong Kong, Macao and Taiwan regions,
Gelonghui FinanceApr 17 04:59 ET
Fosun Pharmaceuticals (600196.SH): Holding subsidiary approved for drug clinical trials
Gelonghui, April 17 | Fosun Pharmaceutical (600196.SH) announced that its holding subsidiary Shanghai Fuhong Hanlin Biotechnology Co., Ltd. and its holding subsidiary recently received approval from the National Drug Administration to conduct clinical trials with HLX53 (i.e. anti-Tigit FC fusion protein) combined with Hans form (i.e. slulizumab injection) and Hanbetai (i.e. bevacizumab injection) for first-line treatment of locally advanced or metastatic hepatocellular carcinoma (HCC). Fu Hong Hanlin plans to launch phase II of this treatment plan in China (excluding Hong Kong, Macao and Taiwan regions) when conditions are met
Gelonghui FinanceApr 17 04:37 ET
復宏漢霖:2023 年度報告
Futu NewsApr 17 04:32 ET · Announcements
No Data
No Data